Proehl Gerald T reported grant involving 170,068 shares of Dermata Therapeutics, Inc. on Aug 16, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
PRESIDENT, CHAIRMAN, CEO
PRESIDENT, CHAIRMAN, CEO
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
170,068Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
292,631Indirect · By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Trade date
Aug 16, 2026Grant
Filed
Aug 18, 2026, 5:25 PM ET2-day reporting delay
Accession
0001493152-26-039048Code A · Transaction 3244
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 16, 2026Grant1,360,544——Trade 3246
Aug 16, 2026Grant170,068——Trade 3248
Aug 16, 2026Grant1,360,544——Trade 3245
Aug 16, 2026Grant170,068——Trade 3247
Aug 16, 2026Grant1,360,544——Trade 3249
6 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

DRMA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DRMA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −7%1w ago −23%1d ago +2.1%
Returns since7d +12%30d −20%90d180d1y

Footnotes in full

F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F6: The pre-funded warrant has no expiration date.